CA2234071C - Intensive homologous promoter obtained from hamsters - Google Patents

Intensive homologous promoter obtained from hamsters Download PDF

Info

Publication number: CA2234071C
Authority: CA; Canada
Prior art keywords: promoter; nucleic acid; gene; acid molecule; sequence
Prior art date: 1995-10-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA002234071A

Other languages

English (en)

French (fr)

Other versions

CA2234071A1 (en

Inventor

Barbara Enenkel

Frank Gannon

Klaus Bergemann

Wolfgang Noe

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Boehringer Ingelheim Pharma GmbH and Co KG

Original Assignee

Dr Karl Thomae GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-10-24

Filing date

1996-10-24

Publication date

2003-01-21

1996-10-24 Application filed by Dr Karl Thomae GmbH filed Critical Dr Karl Thomae GmbH

1997-05-01 Publication of CA2234071A1 publication Critical patent/CA2234071A1/en

2003-01-21 Application granted granted Critical

2003-01-21 Publication of CA2234071C publication Critical patent/CA2234071C/en

2016-10-24 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

241000699800 Cricetinae Species 0.000 title claims abstract description 43
108090000623 proteins and genes Proteins 0.000 claims abstract description 107
210000004027 cell Anatomy 0.000 claims abstract description 76
210000004978 chinese hamster ovary cell Anatomy 0.000 claims abstract description 47
238000000034 method Methods 0.000 claims abstract description 38
230000008569 process Effects 0.000 claims abstract description 22
108020004707 nucleic acids Proteins 0.000 claims description 49
102000039446 nucleic acids Human genes 0.000 claims description 49
150000007523 nucleic acids Chemical class 0.000 claims description 49
230000000694 effects Effects 0.000 claims description 47
230000001105 regulatory effect Effects 0.000 claims description 28
238000012217 deletion Methods 0.000 claims description 18
230000037430 deletion Effects 0.000 claims description 18
239000003623 enhancer Substances 0.000 claims description 15
102000004169 proteins and genes Human genes 0.000 claims description 14
108060003951 Immunoglobulin Proteins 0.000 claims description 11
102000018358 immunoglobulin Human genes 0.000 claims description 11
108700026226 TATA Box Proteins 0.000 claims description 9
230000003321 amplification Effects 0.000 claims description 7
239000013604 expression vector Substances 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 7
238000003199 nucleic acid amplification method Methods 0.000 claims description 7
230000005758 transcription activity Effects 0.000 claims description 7
102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 6
108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 6
230000000295 complement effect Effects 0.000 claims description 6
238000003780 insertion Methods 0.000 claims description 6
230000037431 insertion Effects 0.000 claims description 6
229960000187 tissue plasminogen activator Drugs 0.000 claims description 6
230000009467 reduction Effects 0.000 claims description 5
102000006601 Thymidine Kinase Human genes 0.000 claims description 4
108020004440 Thymidine kinase Proteins 0.000 claims description 4
230000001737 promoting effect Effects 0.000 claims description 4
238000006467 substitution reaction Methods 0.000 claims description 4
102100032912 CD44 antigen Human genes 0.000 claims description 3
102000003951 Erythropoietin Human genes 0.000 claims description 3
108090000394 Erythropoietin Proteins 0.000 claims description 3
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 3
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 3
101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 3
102000014150 Interferons Human genes 0.000 claims description 3
108010050904 Interferons Proteins 0.000 claims description 3
102000019197 Superoxide Dismutase Human genes 0.000 claims description 3
108010012715 Superoxide dismutase Proteins 0.000 claims description 3
102000018594 Tumour necrosis factor Human genes 0.000 claims description 3
108050007852 Tumour necrosis factor Proteins 0.000 claims description 3
229940105423 erythropoietin Drugs 0.000 claims description 3
229940079322 interferon Drugs 0.000 claims description 3
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 3
208000009889 Herpes Simplex Diseases 0.000 claims description 2
230000006798 recombination Effects 0.000 claims description 2
238000005215 recombination Methods 0.000 claims description 2
FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 claims 1
108020001507 fusion proteins Proteins 0.000 abstract description 6
102000037865 fusion proteins Human genes 0.000 abstract description 6
101000849522 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 40S ribosomal protein S13 Proteins 0.000 description 39
239000013598 vector Substances 0.000 description 35
239000012634 fragment Substances 0.000 description 33
230000014509 gene expression Effects 0.000 description 29
108090000848 Ubiquitin Proteins 0.000 description 28
102000044159 Ubiquitin Human genes 0.000 description 25
108091026898 Leader sequence (mRNA) Proteins 0.000 description 24
108020004414 DNA Proteins 0.000 description 23
239000002299 complementary DNA Substances 0.000 description 23
239000000047 product Substances 0.000 description 21
239000002773 nucleotide Substances 0.000 description 20
125000003729 nucleotide group Chemical group 0.000 description 20
239000013612 plasmid Substances 0.000 description 17
210000002966 serum Anatomy 0.000 description 16
150000001413 amino acids Chemical class 0.000 description 15
238000013518 transcription Methods 0.000 description 14
230000035897 transcription Effects 0.000 description 14
239000000523 sample Substances 0.000 description 12
238000005520 cutting process Methods 0.000 description 11
238000009396 hybridization Methods 0.000 description 11
239000002609 medium Substances 0.000 description 11
230000003612 virological effect Effects 0.000 description 11
108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
241000282414 Homo sapiens Species 0.000 description 10
101710163270 Nuclease Proteins 0.000 description 10
238000010367 cloning Methods 0.000 description 10
108700039691 Genetic Promoter Regions Proteins 0.000 description 9
108010000605 Ribosomal Proteins Proteins 0.000 description 9
238000013507 mapping Methods 0.000 description 9
238000011160 research Methods 0.000 description 9
238000012163 sequencing technique Methods 0.000 description 9
230000029087 digestion Effects 0.000 description 8
238000001890 transfection Methods 0.000 description 8
108010068086 Polyubiquitin Proteins 0.000 description 7
102000002278 Ribosomal Proteins Human genes 0.000 description 7
108091081024 Start codon Proteins 0.000 description 7
238000004458 analytical method Methods 0.000 description 7
108010052305 exodeoxyribonuclease III Proteins 0.000 description 7
108020004999 messenger RNA Proteins 0.000 description 7
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
108700008625 Reporter Genes Proteins 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
238000010230 functional analysis Methods 0.000 description 6
230000004927 fusion Effects 0.000 description 6
RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 6
108091028043 Nucleic acid sequence Proteins 0.000 description 5
238000003556 assay Methods 0.000 description 5
210000004962 mammalian cell Anatomy 0.000 description 5
241000894007 species Species 0.000 description 5
238000011144 upstream manufacturing Methods 0.000 description 5
108700028146 Genetic Enhancer Elements Proteins 0.000 description 4
101150055766 cat gene Proteins 0.000 description 4
230000001086 cytosolic effect Effects 0.000 description 4
239000000499 gel Substances 0.000 description 4
239000012679 serum free medium Substances 0.000 description 4
108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 3
108091026890 Coding region Proteins 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
108091092195 Intron Proteins 0.000 description 3
SJNZALDHDUYDBU-IHRRRGAJSA-N Lys-Arg-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(O)=O SJNZALDHDUYDBU-IHRRRGAJSA-N 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
238000000636 Northern blotting Methods 0.000 description 3
239000004677 Nylon Substances 0.000 description 3
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
102100037935 Polyubiquitin-C Human genes 0.000 description 3
241000700584 Simplexvirus Species 0.000 description 3
238000007792 addition Methods 0.000 description 3
108010047495 alanylglycine Proteins 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 3
230000012010 growth Effects 0.000 description 3
238000011534 incubation Methods 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
230000010354 integration Effects 0.000 description 3
238000002955 isolation Methods 0.000 description 3
239000003550 marker Substances 0.000 description 3
239000012528 membrane Substances 0.000 description 3
239000013642 negative control Substances 0.000 description 3
229920001778 nylon Polymers 0.000 description 3
229920002401 polyacrylamide Polymers 0.000 description 3
229950010131 puromycin Drugs 0.000 description 3
230000010076 replication Effects 0.000 description 3
238000012360 testing method Methods 0.000 description 3
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
108020005544 Antisense RNA Proteins 0.000 description 2
101000587984 Arabidopsis thaliana Protein SPOROCYTELESS Proteins 0.000 description 2
ITHMWNNUDPJJER-ULQDDVLXSA-N Arg-His-Tyr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ITHMWNNUDPJJER-ULQDDVLXSA-N 0.000 description 2
OLVIPTLKNSAYRJ-YUMQZZPRSA-N Asn-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N OLVIPTLKNSAYRJ-YUMQZZPRSA-N 0.000 description 2
RZNAMKZJPBQWDJ-SRVKXCTJSA-N Asn-Lys-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)N RZNAMKZJPBQWDJ-SRVKXCTJSA-N 0.000 description 2
YNCHFVRXEQFPBY-BQBZGAKWSA-N Asp-Gly-Arg Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N YNCHFVRXEQFPBY-BQBZGAKWSA-N 0.000 description 2
241000699802 Cricetulus griseus Species 0.000 description 2
ZIKWRNJXFIQECJ-CIUDSAMLSA-N Cys-Cys-Leu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(O)=O ZIKWRNJXFIQECJ-CIUDSAMLSA-N 0.000 description 2
CVLIHKBUPSFRQP-WHFBIAKZSA-N Cys-Gly-Ala Chemical compound [H]N[C@@H](CS)C(=O)NCC(=O)N[C@@H](C)C(O)=O CVLIHKBUPSFRQP-WHFBIAKZSA-N 0.000 description 2
DZSICRGTVPDCRN-YUMQZZPRSA-N Cys-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CS)N DZSICRGTVPDCRN-YUMQZZPRSA-N 0.000 description 2
239000003298 DNA probe Substances 0.000 description 2
102100024746 Dihydrofolate reductase Human genes 0.000 description 2
QKCZZAZNMMVICF-DCAQKATOSA-N Gln-Leu-Glu Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O QKCZZAZNMMVICF-DCAQKATOSA-N 0.000 description 2
OWVURWCRZZMAOZ-XHNCKOQMSA-N Glu-Cys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)O)N)C(=O)O OWVURWCRZZMAOZ-XHNCKOQMSA-N 0.000 description 2
CUXJIASLBRJOFV-LAEOZQHASA-N Glu-Gly-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O CUXJIASLBRJOFV-LAEOZQHASA-N 0.000 description 2
JWNZHMSRZXXGTM-XKBZYTNZSA-N Glu-Ser-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JWNZHMSRZXXGTM-XKBZYTNZSA-N 0.000 description 2
LZEUDRYSAZAJIO-AUTRQRHGSA-N Glu-Val-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O LZEUDRYSAZAJIO-AUTRQRHGSA-N 0.000 description 2
BNMRSWQOHIQTFL-JSGCOSHPSA-N Gly-Val-Phe Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 BNMRSWQOHIQTFL-JSGCOSHPSA-N 0.000 description 2
RLAOTFTXBFQJDV-KKUMJFAQSA-N His-Phe-Asp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(O)=O)C(O)=O)C1=CN=CN1 RLAOTFTXBFQJDV-KKUMJFAQSA-N 0.000 description 2
241000701024 Human betaherpesvirus 5 Species 0.000 description 2
241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
JHNJNTMTZHEDLJ-NAKRPEOUSA-N Ile-Ser-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O JHNJNTMTZHEDLJ-NAKRPEOUSA-N 0.000 description 2
108010065920 Insulin Lispro Proteins 0.000 description 2
NTRAGDHVSGKUSF-AVGNSLFASA-N Leu-Arg-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O NTRAGDHVSGKUSF-AVGNSLFASA-N 0.000 description 2
CSFVADKICPDRRF-KKUMJFAQSA-N Leu-His-Leu Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C([O-])=O)CC1=CN=CN1 CSFVADKICPDRRF-KKUMJFAQSA-N 0.000 description 2
YDDDRTIPNTWGIG-SRVKXCTJSA-N Lys-Lys-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O YDDDRTIPNTWGIG-SRVKXCTJSA-N 0.000 description 2
NYTDJEZBAAFLLG-IHRRRGAJSA-N Lys-Val-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(O)=O NYTDJEZBAAFLLG-IHRRRGAJSA-N 0.000 description 2
WXHHTBVYQOSYSL-FXQIFTODSA-N Met-Ala-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O WXHHTBVYQOSYSL-FXQIFTODSA-N 0.000 description 2
AWOMRHGUWFBDNU-ZPFDUUQYSA-N Met-Gln-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCSC)N AWOMRHGUWFBDNU-ZPFDUUQYSA-N 0.000 description 2
XZFYRXDAULDNFX-UHFFFAOYSA-N N-L-cysteinyl-L-phenylalanine Natural products SCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XZFYRXDAULDNFX-UHFFFAOYSA-N 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
KAHUBGWSIQNZQQ-KKUMJFAQSA-N Phe-Asn-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 KAHUBGWSIQNZQQ-KKUMJFAQSA-N 0.000 description 2
RGMLUHANLDVMPB-ULQDDVLXSA-N Phe-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N RGMLUHANLDVMPB-ULQDDVLXSA-N 0.000 description 2
MGDFPGCFVJFITQ-CIUDSAMLSA-N Pro-Glu-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O MGDFPGCFVJFITQ-CIUDSAMLSA-N 0.000 description 2
DWGFLKQSGRUQTI-IHRRRGAJSA-N Pro-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1 DWGFLKQSGRUQTI-IHRRRGAJSA-N 0.000 description 2
FHZJRBVMLGOHBX-GUBZILKMSA-N Pro-Pro-Asp Chemical compound OC(=O)C[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1)C(O)=O FHZJRBVMLGOHBX-GUBZILKMSA-N 0.000 description 2
GMJDSFYVTAMIBF-FXQIFTODSA-N Pro-Ser-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O GMJDSFYVTAMIBF-FXQIFTODSA-N 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
FTVRVZNYIYWJGB-ACZMJKKPSA-N Ser-Asp-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O FTVRVZNYIYWJGB-ACZMJKKPSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
XTCNBOBTROGWMW-RWRJDSDZSA-N Thr-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N XTCNBOBTROGWMW-RWRJDSDZSA-N 0.000 description 2
YOOAQCZYZHGUAZ-KATARQTJSA-N Thr-Leu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YOOAQCZYZHGUAZ-KATARQTJSA-N 0.000 description 2
VRUFCJZQDACGLH-UVOCVTCTSA-N Thr-Leu-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VRUFCJZQDACGLH-UVOCVTCTSA-N 0.000 description 2
OMRWDMWXRWTQIU-YJRXYDGGSA-N Thr-Tyr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CS)C(=O)O)N)O OMRWDMWXRWTQIU-YJRXYDGGSA-N 0.000 description 2
108091036066 Three prime untranslated region Proteins 0.000 description 2
108010018242 Transcription Factor AP-1 Proteins 0.000 description 2
108091023040 Transcription factor Proteins 0.000 description 2
102000040945 Transcription factor Human genes 0.000 description 2
102100023132 Transcription factor Jun Human genes 0.000 description 2
102100030246 Transcription factor Sp1 Human genes 0.000 description 2
101710085924 Transcription factor Sp1 Proteins 0.000 description 2
KLQPIEVIKOQRAW-IZPVPAKOSA-N Tyr-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N)O KLQPIEVIKOQRAW-IZPVPAKOSA-N 0.000 description 2
QVYFTFIBKCDHIE-ACRUOGEOSA-N Tyr-Tyr-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCCN)C(=O)O)N)O QVYFTFIBKCDHIE-ACRUOGEOSA-N 0.000 description 2
VLOYGOZDPGYWFO-LAEOZQHASA-N Val-Asp-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O VLOYGOZDPGYWFO-LAEOZQHASA-N 0.000 description 2
OTJMMKPMLUNTQT-AVGNSLFASA-N Val-Leu-Arg Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](C(C)C)N OTJMMKPMLUNTQT-AVGNSLFASA-N 0.000 description 2
AEMPCGRFEZTWIF-IHRRRGAJSA-N Val-Leu-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O AEMPCGRFEZTWIF-IHRRRGAJSA-N 0.000 description 2
108010013835 arginine glutamate Proteins 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
239000003184 complementary RNA Substances 0.000 description 2
230000000875 corresponding effect Effects 0.000 description 2
108091092330 cytoplasmic RNA Proteins 0.000 description 2
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
230000002950 deficient Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
108020001096 dihydrofolate reductase Proteins 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
210000003527 eukaryotic cell Anatomy 0.000 description 2
239000000284 extract Substances 0.000 description 2
238000000605 extraction Methods 0.000 description 2
238000010353 genetic engineering Methods 0.000 description 2
108010042598 glutamyl-aspartyl-glycine Proteins 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000011835 investigation Methods 0.000 description 2
108010031424 isoleucyl-prolyl-proline Proteins 0.000 description 2
238000002372 labelling Methods 0.000 description 2
108010047926 leucyl-lysyl-tyrosine Proteins 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
108010054155 lysyllysine Proteins 0.000 description 2
108010016686 methionyl-alanyl-serine Proteins 0.000 description 2
239000000178 monomer Substances 0.000 description 2
230000035772 mutation Effects 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
230000037361 pathway Effects 0.000 description 2
230000008488 polyadenylation Effects 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
230000002028 premature Effects 0.000 description 2
108091008146 restriction endonucleases Proteins 0.000 description 2
238000010839 reverse transcription Methods 0.000 description 2
230000010474 transient expression Effects 0.000 description 2
238000003146 transient transfection Methods 0.000 description 2
230000014616 translation Effects 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
238000005406 washing Methods 0.000 description 2
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
108020005029 5' Flanking Region Proteins 0.000 description 1
108010016219 Acetyl-CoA carboxylase Proteins 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
BLIMFWGRQKRCGT-YUMQZZPRSA-N Ala-Gly-Lys Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCCN BLIMFWGRQKRCGT-YUMQZZPRSA-N 0.000 description 1
XHNLCGXYBXNRIS-BJDJZHNGSA-N Ala-Lys-Ile Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O XHNLCGXYBXNRIS-BJDJZHNGSA-N 0.000 description 1
VCSABYLVNWQYQE-SRVKXCTJSA-N Ala-Lys-Lys Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@@H](CCCCN)C(O)=O VCSABYLVNWQYQE-SRVKXCTJSA-N 0.000 description 1
HJVGMOYJDDXLMI-AVGNSLFASA-N Arg-Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCCNC(N)=N HJVGMOYJDDXLMI-AVGNSLFASA-N 0.000 description 1
RCFGLXMZDYNRSC-CIUDSAMLSA-N Asn-Lys-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O RCFGLXMZDYNRSC-CIUDSAMLSA-N 0.000 description 1
LMIWYCWRJVMAIQ-NHCYSSNCSA-N Asn-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N LMIWYCWRJVMAIQ-NHCYSSNCSA-N 0.000 description 1
NJLLRXWFPQQPHV-SRVKXCTJSA-N Asp-Tyr-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O NJLLRXWFPQQPHV-SRVKXCTJSA-N 0.000 description 1
108010018763 Biotin carboxylase Proteins 0.000 description 1
238000009010 Bradford assay Methods 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
101000986346 Chironomus tentans High mobility group protein I Proteins 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
KZEUVLLVULIPNX-GUBZILKMSA-N Gln-Asp-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)N KZEUVLLVULIPNX-GUBZILKMSA-N 0.000 description 1
NKCZYEDZTKOFBG-GUBZILKMSA-N Gln-Gln-Arg Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O NKCZYEDZTKOFBG-GUBZILKMSA-N 0.000 description 1
KVXVVDFOZNYYKZ-DCAQKATOSA-N Gln-Gln-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O KVXVVDFOZNYYKZ-DCAQKATOSA-N 0.000 description 1
TWIAMTNJOMRDAK-GUBZILKMSA-N Gln-Lys-Asp Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O TWIAMTNJOMRDAK-GUBZILKMSA-N 0.000 description 1
JBRBACJPBZNFMF-YUMQZZPRSA-N Gly-Ala-Lys Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN JBRBACJPBZNFMF-YUMQZZPRSA-N 0.000 description 1
KFMBRBPXHVMDFN-UWVGGRQHSA-N Gly-Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCNC(N)=N KFMBRBPXHVMDFN-UWVGGRQHSA-N 0.000 description 1
FXGRXIATVXUAHO-WEDXCCLWSA-N Gly-Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCCN FXGRXIATVXUAHO-WEDXCCLWSA-N 0.000 description 1
101000840051 Homo sapiens Ubiquitin-60S ribosomal protein L40 Proteins 0.000 description 1
LKACSKJPTFSBHR-MNXVOIDGSA-N Ile-Gln-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N LKACSKJPTFSBHR-MNXVOIDGSA-N 0.000 description 1
HQEPKOFULQTSFV-JURCDPSOSA-N Ile-Phe-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)O)N HQEPKOFULQTSFV-JURCDPSOSA-N 0.000 description 1
KBDIBHQICWDGDL-PPCPHDFISA-N Ile-Thr-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)O)N KBDIBHQICWDGDL-PPCPHDFISA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
101150118523 LYS4 gene Proteins 0.000 description 1
KSZCCRIGNVSHFH-UWVGGRQHSA-N Leu-Arg-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O KSZCCRIGNVSHFH-UWVGGRQHSA-N 0.000 description 1
VWHGTYCRDRBSFI-ZETCQYMHSA-N Leu-Gly-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)NCC(O)=O VWHGTYCRDRBSFI-ZETCQYMHSA-N 0.000 description 1
QLDHBYRUNQZIJQ-DKIMLUQUSA-N Leu-Ile-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O QLDHBYRUNQZIJQ-DKIMLUQUSA-N 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
239000005089 Luciferase Substances 0.000 description 1
OJDFAABAHBPVTH-MNXVOIDGSA-N Lys-Ile-Gln Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(O)=O OJDFAABAHBPVTH-MNXVOIDGSA-N 0.000 description 1
DLCAXBGXGOVUCD-PPCPHDFISA-N Lys-Thr-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O DLCAXBGXGOVUCD-PPCPHDFISA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
102000003792 Metallothionein Human genes 0.000 description 1
108090000157 Metallothionein Proteins 0.000 description 1
108700005084 Multigene Family Proteins 0.000 description 1
101100090557 Mus musculus Rpl7a gene Proteins 0.000 description 1
WYBVBIHNJWOLCJ-UHFFFAOYSA-N N-L-arginyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCCN=C(N)N WYBVBIHNJWOLCJ-UHFFFAOYSA-N 0.000 description 1
108020005187 Oligonucleotide Probes Proteins 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
239000001888 Peptone Substances 0.000 description 1
108010080698 Peptones Proteins 0.000 description 1
102000001938 Plasminogen Activators Human genes 0.000 description 1
108010001014 Plasminogen Activators Proteins 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
241000714474 Rous sarcoma virus Species 0.000 description 1
102100023361 SAP domain-containing ribonucleoprotein Human genes 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
101800002927 Small subunit Proteins 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
241000913727 Streptomyces alboniger Species 0.000 description 1
101710139423 THO complex subunit 1 Proteins 0.000 description 1
RFKVQLIXNVEOMB-WEDXCCLWSA-N Thr-Leu-Gly Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)O)N)O RFKVQLIXNVEOMB-WEDXCCLWSA-N 0.000 description 1
108010022394 Threonine synthase Proteins 0.000 description 1
MTEQZJFSEMXXRK-CFMVVWHZSA-N Tyr-Asn-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)N MTEQZJFSEMXXRK-CFMVVWHZSA-N 0.000 description 1
102100023341 Ubiquitin-40S ribosomal protein S27a Human genes 0.000 description 1
BMGOFDMKDVVGJG-NHCYSSNCSA-N Val-Asp-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N BMGOFDMKDVVGJG-NHCYSSNCSA-N 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
108091006088 activator proteins Proteins 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
230000003698 anagen phase Effects 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
238000013459 approach Methods 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000002457 bidirectional effect Effects 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
238000010805 cDNA synthesis kit Methods 0.000 description 1
229960005084 calcitriol Drugs 0.000 description 1
GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
244000309466 calf Species 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
230000008859 change Effects 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
101150040312 cho gene Proteins 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
201000010989 colorectal carcinoma Diseases 0.000 description 1
238000010276 construction Methods 0.000 description 1
238000012937 correction Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
102000004419 dihydrofolate reductase Human genes 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
238000010195 expression analysis Methods 0.000 description 1
239000011888 foil Substances 0.000 description 1
238000012215 gene cloning Methods 0.000 description 1
238000012252 genetic analysis Methods 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
229910001385 heavy metal Inorganic materials 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
229910052741 iridium Inorganic materials 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
210000002429 large intestine Anatomy 0.000 description 1
210000001069 large ribosome subunit Anatomy 0.000 description 1
108010044311 leucyl-glycyl-glycine Proteins 0.000 description 1
108010009298 lysylglutamic acid Proteins 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
231100000219 mutagenic Toxicity 0.000 description 1
230000003505 mutagenic effect Effects 0.000 description 1
239000002751 oligonucleotide probe Substances 0.000 description 1
230000008520 organization Effects 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
235000019319 peptone Nutrition 0.000 description 1
230000002688 persistence Effects 0.000 description 1
229940127126 plasminogen activator Drugs 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000037452 priming Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
235000019833 protease Nutrition 0.000 description 1
108020001775 protein parts Proteins 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
108010045647 puromycin N-acetyltransferase Proteins 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
229930002330 retinoic acid Natural products 0.000 description 1
238000012552 review Methods 0.000 description 1
108010011179 ribosomal protein S27a Proteins 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
230000028706 ribosome biogenesis Effects 0.000 description 1
IOVGROKTTNBUGK-SJCJKPOMSA-N ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 description 1
238000005185 salting out Methods 0.000 description 1
230000035939 shock Effects 0.000 description 1
210000001812 small ribosome subunit Anatomy 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
230000010473 stable expression Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000004114 suspension culture Methods 0.000 description 1
229940037128 systemic glucocorticoids Drugs 0.000 description 1
108010061238 threonyl-glycine Proteins 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
230000014621 translational initiation Effects 0.000 description 1
229960001727 tretinoin Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Wood Science & Technology (AREA)
Biophysics (AREA)
Biomedical Technology (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

CA002234071A 1995-10-24 1996-10-24 Intensive homologous promoter obtained from hamsters Expired - Lifetime CA2234071C (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE19539493A DE19539493A1 (de)	1995-10-24	1995-10-24	Starker homologer Promotor aus Hamster
DE19539493.3		1995-10-24
PCT/EP1996/004631 WO1997015664A1 (de)	1995-10-24	1996-10-24	Starker homologer promotor aus hamster

Publications (2)

Publication Number	Publication Date
CA2234071A1 CA2234071A1 (en)	1997-05-01
CA2234071C true CA2234071C (en)	2003-01-21

Family

ID=7775593

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002234071A Expired - Lifetime CA2234071C (en)	1995-10-24	1996-10-24	Intensive homologous promoter obtained from hamsters

Country Status (11)

Country	Link
US (1)	US6063598A (2)
EP (2)	EP1803815A3 (2)
JP (2)	JP3966903B2 (2)
AT (1)	ATE355370T1 (2)
CA (1)	CA2234071C (2)
DE (2)	DE19539493A1 (2)
DK (1)	DK0857211T3 (2)
ES (1)	ES2281905T3 (2)
MX (1)	MX9802764A (2)
PT (1)	PT857211E (2)
WO (1)	WO1997015664A1 (2)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7833787B2 (en)	2003-08-19	2010-11-16	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Method for recloning Chinese hamster ovary (CHO) cells

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0961830A1 (en) *	1997-01-29	1999-12-08	Neurosearch A/S	EXPRESSION VECTORS AND METHODS FOR $i(IN VIVO) EXPRESSION OF THERAPEUTIC POLYPEPTIDES
EP1624067A3 (en) *	2000-09-18	2006-03-15	Genzyme Corporation	Expression vectors containing hybrid ubiquitin promoters
AU2001290984A1 (en) *	2000-09-18	2002-04-02	Genzyme Corporation	Expression vectors containing hybrid ubiquitin promoters
ATE466941T1 (de) *	2001-07-04	2010-05-15	Chromagenics Bv	Dns-sequenzen mit anti-repressor-aktivität
US7384744B2 (en)	2002-11-29	2008-06-10	Boehringer Ingelheim Pharma Gmbh & Co., Kg	Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
US7344886B2 (en)	2002-11-29	2008-03-18	Boehringer Ingelheim Pharma Gmbh & Co., Kg	Neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product
DE10256083A1 (de)	2002-11-29	2004-08-12	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Expressionsvektor, Verfahren zur Herstellung von heterologen Genprodukten und Selektionsverfahren für hochproduzierende rekombinante Zellen
US8669109B2 (en)	2003-08-19	2014-03-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Methods of producing proteins in Chinese hamster ovary (CHO) cells
US20050101017A1 (en) *	2003-11-10	2005-05-12	Wojtek Auerbach	Method of improving gene targeting using a ubiquitin promoter
GB0509965D0 (en) *	2005-05-17	2005-06-22	Ml Lab Plc	Improved expression elements
US9163257B2 (en) *	2005-06-20	2015-10-20	Cadila Healthcare Limited	Expression vector and methods of producing high levels of proteins
EP1806365A1 (en)	2006-01-05	2007-07-11	Boehringer Ingelheim International GmbH	Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
US20080124760A1 (en) *	2006-07-26	2008-05-29	Barbara Enenkel	Regulatory Nucleic Acid Elements
US8609820B2 (en)	2011-10-28	2013-12-17	Neotope Biosciences Limited	Humanized antibodies that recognize alpha-synuclein
NZ629296A (en)	2012-01-27	2016-06-24	Prothena Biosciences Ltd	Humanized antibodies that recognize alpha-synuclein
UA118441C2 (uk)	2012-10-08	2019-01-25	Протена Біосаєнсиз Лімітед	Антитіло, що розпізнає альфа-синуклеїн
EP2938726B1 (en)	2012-12-31	2017-09-27	Boehringer Ingelheim International GmbH	Heterologous intron within a signal peptide
WO2014102101A1 (en)	2012-12-31	2014-07-03	Boehringer Ingelheim International Gmbh	Novel intron sequences
CA2902026C (en)	2013-03-13	2023-08-29	Prothena Biosciences Limited	Tau immunotherapy
US9989540B2 (en)	2013-05-10	2018-06-05	The Regents Of The University Of California	Diagnostic and monitoring system for Huntington's disease
US10513555B2 (en)	2013-07-04	2019-12-24	Prothena Biosciences Limited	Antibody formulations and methods
US9951131B2 (en)	2013-07-12	2018-04-24	Prothena Biosciences Limited	Antibodies that recognize IAPP
US9850302B2 (en)	2013-07-12	2017-12-26	Prothena Biosciences Limited	Antibodies that recognize IAPP
EP3071974A2 (en)	2013-11-19	2016-09-28	Prothena Biosciences Limited	Monitoring immunotherapy of lewy body disease from constipation symptoms
EP3089760B1 (en)	2013-12-31	2020-01-15	ProteoNic Biotechnology IP B.V.	Construct and sequence for enhanced gene expression
PT3116911T (pt)	2014-03-12	2019-09-04	Prothena Biosciences Ltd	Anticorpos anti-mcam e métodos de utilização associados
KR20160131082A (ko)	2014-03-12	2016-11-15	프로테나 바이오사이언시즈 리미티드	Lg1-3에 특이적인 항-라미닌4 항체
TW201623331A (zh)	2014-03-12	2016-07-01	普羅帝納生物科學公司	抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
US10059761B2 (en)	2014-03-12	2018-08-28	Prothena Biosciences Limited	Anti-Laminin4 antibodies specific for LG4-5
JP6744856B2 (ja)	2014-04-08	2020-08-19	プロセナ・バイオサイエンシズ・リミテッド	α−シヌクレインを認識する抗体を含む血液脳関門シャトル
HRP20230405T8 (hr)	2014-12-10	2023-09-29	Opko Biologics Ltd.	Metode proizvodnje dugo djelujućih ctp-modificiranih polipeptida hormona rasta
TWI769570B (zh)	2015-01-28	2022-07-01	愛爾蘭商普羅佘納生物科技有限公司	抗甲狀腺素運送蛋白抗體
TWI786505B (zh)	2015-01-28	2022-12-11	愛爾蘭商普羅佘納生物科技有限公司	抗甲狀腺素運送蛋白抗體
TWI718121B (zh)	2015-01-28	2021-02-11	愛爾蘭商普羅佘納生物科技有限公司	抗甲狀腺素運送蛋白抗體
WO2016186879A1 (en)	2015-05-18	2016-11-24	Zymtronix, Llc	Magnetically immobilized microbiocidal enzymes
EP3323166B1 (en)	2015-07-15	2024-03-13	ZYMtronix, Inc.	Automated bionanocatalyst production
WO2017046774A2 (en)	2015-09-16	2017-03-23	Prothena Biosciences Limited	Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017046776A2 (en)	2015-09-16	2017-03-23	Prothena Biosciences Limited	Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017149513A1 (en)	2016-03-03	2017-09-08	Prothena Biosciences Limited	Anti-mcam antibodies and associated methods of use
WO2017153953A1 (en)	2016-03-09	2017-09-14	Prothena Biosciences Limited	Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153955A1 (en)	2016-03-09	2017-09-14	Prothena Biosciences Limited	Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
PE20190208A1 (es)	2016-05-02	2019-02-07	Prothena Biosciences Ltd	Anticuerpos que reconocen tau
CA3022515A1 (en)	2016-05-02	2017-11-09	Prothena Biosciences Limited	Antibodies recognizing tau
EP3452507B1 (en)	2016-05-02	2022-10-19	Prothena Biosciences Limited	Tau immunotherapy
WO2017208210A1 (en)	2016-06-03	2017-12-07	Prothena Biosciences Limited	Anti-mcam antibodies and associated methods of use
JP7017013B2 (ja)	2016-07-02	2022-02-08	プロセナバイオサイエンシーズリミテッド	抗トランスサイレチン抗体
WO2018007923A2 (en)	2016-07-02	2018-01-11	Prothena Biosciences Limited	Anti-transthyretin antibodies
WO2018007922A2 (en)	2016-07-02	2018-01-11	Prothena Biosciences Limited	Anti-transthyretin antibodies
MY206271A (en)	2016-07-11	2024-12-06	Opko Biologics Ltd	Long-acting coagulation factor vii and methods of producing same
CA3031802A1 (en)	2016-08-13	2018-02-22	Zymtronix Catalytic Systems, Inc.	Magnetically immobilized biocidal enzymes and biocidal chemicals
CN110177869A (zh)	2017-01-13	2019-08-27	加利福尼亚大学董事会	免疫改造的多能细胞
CN110881274B (zh)	2017-05-02	2024-11-15	普罗塞纳生物科学有限公司	识别tau的抗体
JP2021502955A (ja)	2017-09-28	2021-02-04	プロセナ・バイオサイエンシズ・リミテッド	シヌクレイン病の治療のための投与レジメン
CN111757730A (zh)	2017-10-06	2020-10-09	普罗塞纳生物科学有限公司	检测甲状腺素运载蛋白的方法
CU20200042A7 (es)	2017-11-29	2021-03-11	Prothena Biosciences Ltd	Formulación liofilizada de un anticuerpo monoclonal contra la transtirretina
US20210263001A1 (en)	2018-09-05	2021-08-26	Zymtronix Catalytic Systems, Inc.	Immobilized enzymes and microsomes on magnetic scaffolds
SG11202104549TA (en)	2018-11-08	2021-05-28	Prothena Biosciences Ltd	Antibodies recognizing tau
CN119684457A (zh)	2018-11-26	2025-03-25	四十七有限责任公司	针对c-kit的人源化抗体
EP3935083A4 (en)	2019-03-03	2022-11-30	Prothena Biosciences Limited	Antibodies recognizing tau
US11162079B2 (en)	2019-05-10	2021-11-02	The Regents Of The University Of California	Blood type O Rh-hypo-immunogenic pluripotent cells
WO2020231882A2 (en)	2019-05-10	2020-11-19	The Regents Of The University Of California	Modified pluripotent cells
US12391923B2 (en)	2019-06-26	2025-08-19	The Regents Of The University Of California	SIRPα-silenced natural killer (NK) cells
JP2022543112A (ja)	2019-08-01	2022-10-07	サナバイオテクノロジー，インコーポレイテッド	Ｄｕｘ４発現細胞およびそれらの使用
AU2020336302A1 (en)	2019-08-23	2022-03-03	Sana Biotechnology, Inc.	CD24 expressing cells and uses thereof
AU2021207810A1 (en)	2020-01-13	2022-08-04	Sana Biotechnology, Inc.	Modification of blood type antigens
EP4585223A3 (en)	2020-01-15	2025-07-30	The Regents of the University of California	Transplanted cell protection via inhibition of polymorphonuclear cells
CA3165076A1 (en)	2020-01-17	2021-07-22	Ryan Clarke	Safety switches for regulation of gene expression
MX2022011831A (es)	2020-03-25	2023-01-04	Sana Biotechnology Inc	Células neurales hipoinmunogénicas para el tratamiento de trastornos y afecciones neurológicas.
CA3183994A1 (en)	2020-06-24	2021-12-30	Philip James Dolan Iii	Antibodies recognizing sortilin
IL300516A (en)	2020-08-13	2023-04-01	Sana Biotechnology Inc	Methods for treating susceptible patients with hypoimmunogenic cells, and related methods and compounds
CA3200509A1 (en)	2020-12-31	2022-07-07	Sonja SCHREPFER	Methods and compositions for modulating car-t activity
BR112023024231A2 (pt)	2021-05-19	2024-01-30	Sana Biotechnology Inc	Células t primárias rhd negativas hipoimunogênicas
AU2022283291A1 (en)	2021-05-27	2023-11-02	Sana Biotechnology, Inc.	Hypoimmunogenic cells comprising engineered hla-e or hla-g
KR20240046319A (ko)	2021-07-14	2024-04-08	사나 바이오테크놀로지, 인크.	저면역원성 세포에서의 y 염색체-연결 항원의 변경된 발현
WO2023019226A1 (en)	2021-08-11	2023-02-16	Sana Biotechnology, Inc.	Genetically modified cells for allogeneic cell therapy
JP2024535677A (ja)	2021-08-11	2024-10-02	サナバイオテクノロジー，インコーポレイテッド	即時血液媒介性炎症反応を減少させるための同種細胞療法を目的とした遺伝子改変細胞
KR20240073006A (ko)	2021-08-11	2024-05-24	사나 바이오테크놀로지, 인크.	동종이계 세포 요법을 위한 유전자 변형된 1차 세포
AU2022325231A1 (en)	2021-08-11	2024-02-08	Sana Biotechnology, Inc.	Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
KR20240155390A (ko)	2022-02-17	2024-10-28	사나 바이오테크놀로지, 인크.	조작된 cd47 단백질 및 이의 용도
US20250101382A1 (en)	2022-03-11	2025-03-27	Sana Biotechnology, Inc.	Genetically modified cells and compositions and uses thereof
WO2023183313A1 (en)	2022-03-22	2023-09-28	Sana Biotechnology, Inc.	Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
WO2024125597A1 (en)	2022-12-14	2024-06-20	Providence Therapeutics Holdings Inc.	Compositions and methods for infectious diseases
WO2024151541A1 (en)	2023-01-09	2024-07-18	Sana Biotechnology, Inc.	Type-1 diabetes autoimmune mouse
WO2024229302A1 (en)	2023-05-03	2024-11-07	Sana Biotechnology, Inc.	Methods of dosing and administration of engineered islet cells
CN121604968A (zh)	2023-05-22	2026-03-03	萨那生物科技公司	递送胰岛细胞的方法及相关方法
AU2024328949A1 (en)	2023-08-23	2026-03-12	Sana Biotechnology, Inc.	Modified cd47 proteins and their uses
AU2024342922A1 (en)	2023-09-15	2026-04-23	Othair Prothena Limited	Cell penetrating agents and uses thereof
TW202525338A (zh)	2023-09-15	2025-07-01	愛爾蘭商普羅希那生物科學有限公司	細胞穿透劑及其用途
AR133828A1 (es)	2023-09-15	2025-11-05	Prothena Biosciences Ltd	Anticuerpos anti-tdp-43 y sus usos
AU2024342899A1 (en)	2023-09-15	2026-04-23	Prothena Platform Technologies Limited	Methods, compositions, and kits including cell-penetrating agents
WO2025166633A2 (en)	2024-02-07	2025-08-14	Westlake Genetech. Ltd.	Split gene editing systems and uses thereof

1995
- 1995-10-24 DE DE19539493A patent/DE19539493A1/de not_active Ceased
1996
- 1996-10-24 ES ES96937224T patent/ES2281905T3/es not_active Expired - Lifetime
- 1996-10-24 US US09/051,969 patent/US6063598A/en not_active Expired - Lifetime
- 1996-10-24 EP EP06126019A patent/EP1803815A3/de not_active Withdrawn
- 1996-10-24 CA CA002234071A patent/CA2234071C/en not_active Expired - Lifetime
- 1996-10-24 AT AT96937224T patent/ATE355370T1/de active
- 1996-10-24 EP EP96937224A patent/EP0857211B1/de not_active Expired - Lifetime
- 1996-10-24 DK DK96937224T patent/DK0857211T3/da active
- 1996-10-24 JP JP51628897A patent/JP3966903B2/ja not_active Expired - Lifetime
- 1996-10-24 PT PT96937224T patent/PT857211E/pt unknown
- 1996-10-24 DE DE59611420T patent/DE59611420D1/de not_active Expired - Lifetime
- 1996-10-24 WO PCT/EP1996/004631 patent/WO1997015664A1/de not_active Ceased
1998
- 1998-04-07 MX MX9802764A patent/MX9802764A/es active IP Right Grant
2006
- 2006-07-07 JP JP2006187719A patent/JP2006320330A/ja active Pending

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7833787B2 (en)	2003-08-19	2010-11-16	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Method for recloning Chinese hamster ovary (CHO) cells

Also Published As

Publication number	Publication date
WO1997015664A1 (de)	1997-05-01
EP0857211A1 (de)	1998-08-12
EP0857211B1 (de)	2007-02-28
DE19539493A1 (de)	1997-04-30
PT857211E (pt)	2007-03-30
ATE355370T1 (de)	2006-03-15
JPH11513572A (ja)	1999-11-24
EP1803815A3 (de)	2007-08-29
DK0857211T3 (da)	2007-03-26
MX9802764A (es)	1998-11-30
EP1803815A2 (de)	2007-07-04
JP2006320330A (ja)	2006-11-30
DE59611420D1 (de)	2007-04-12
CA2234071A1 (en)	1997-05-01
JP3966903B2 (ja)	2007-08-29
ES2281905T3 (es)	2007-10-01
US6063598A (en)	2000-05-16

Legal Events

Date	Code	Title	Description
2001-05-11	EEER	Examination request
2016-12-26	MKEX	Expiry	Effective date: 20161024

Publication	Publication Date	Title
CA2234071C (en)	2003-01-21	Intensive homologous promoter obtained from hamsters
McBurney et al.	1991	The mouse Pgk-1 gene promoter contains an upstream activator sequence
AU692196B2 (en)	1998-06-04	Translational enhancer DNA
CN101517085B (zh)	2013-08-07	调控性核酸元件
Villa-Garcia et al.	1994	Isolation and characterization of a TATA-less promoter for the human beta 3 integrin gene
US20030074684A1 (en)	2003-04-17	Control of gene expression
Ichinose et al.	1992	Tissue-specific alternative splicing of the first exon generates two types of mRNAs in human aromatic L-amino acid decarboxylase
PL195604B1 (pl)	2007-10-31	Oczyszczony i wyizolowany DNA, komórka gospodarza, wektor, chimeryczny polinukleotyd, plazmidy orazsposób zwiększania transkrypcji
Gavalas et al.	1993	Coexpression of two closely linked avian genes for purine nucleotide synthesis from a bidirectional promoter
AU680551B2 (en)	1997-07-31	Glycerin-3-phosphate-dehydrogenase (GPDH)
AU2010334886B2 (en)	2014-04-24	Promoter sequences
AU682253B2 (en)	1997-09-25	CD 69 transcriptional regulatory elements
Chien et al.	1998	Phosphate depletion enhances the stability of the amphotropic murine leukemia virus receptor mRNA
CA2203613C (en)	2008-01-15	Secreted .alpha.-amylase as a reporter gene
IE904639A1 (en)	1991-07-17	Bovine myogenic factor gene
JP4642865B2 (ja)	2011-03-02	新規制御エレメントを含むベクター
EP0496453A1 (en)	1992-07-29	Human glut4 gene promoter
JP2681253B2 (ja)	1997-11-26	ペルオキシダ−ゼ転写調節遺伝子及びその利用方法
JP3144097B2 (ja)	2001-03-07	新規なタンパク質およびそれをコードする遺伝子
AU9522501A (en)	2002-01-31	Control of gene expression
AU2001100608B4 (en)	2002-05-02	Control of gene expression
Nagaoka et al.	1993	Cloning and characterization of the guinea pig neutrophil cationic peptide-1 and-2 genes
Albor et al.	1995	The Gnb5 gene is a novel β-transducin homolog transcribed from a divergent promoter located immediately upstream of the Syrian hamster p53 P1 promoter
HK1134107B (en)	2014-04-17	Regulatory nucleic acid elements
MXPA06005307A (en)	2006-10-17	Plasmid system for multigene expression

CA2234071C - Intensive homologous promoter obtained from hamsters - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (3)

Publications (2)

Family

ID=7775593

Family Applications (1)

Country Status (11)

Cited By (1)

Families Citing this family (91)

Cited By (1)

Also Published As

Similar Documents

Legal Events